Shared on 13 Nov 25
Fair value Increased 0.78%PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts
Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.
Shared on 30 Apr 25
Fair value Decreased 1.37%AnalystConsensusTarget has decreased revenue growth from -1.2% to -1.0%.
Shared on 09 Apr 25
Fair value Decreased 1.67%AnalystConsensusTarget has decreased revenue growth from -0.9% to -1.0%.
Shared on 02 Apr 25
Fair value Decreased 2.14%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Decreased 0.16%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 0.064%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Mar 25
Fair value Increased 0.87%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Decreased 6.42%AnalystConsensusTarget has decreased revenue growth from 1.9% to -0.9%.